Gilead Science (GILD.US), a US biotech company gains over 10% at the start of the Wall Street session, based on information about the possible high efficacy of Remdesivir drug for coronavirus. The drug was previously used to treat other viruses, such as Eboli or SARS or MERS. According to the company, the drug is expected to significantly weaken the effect of coronavirus and lead to faster recovery of patients. Attempts to treat people infected with coronavirus with Remdesivir have been conducted on a small sample and involved people with rather mild symptoms, so scientists are asking to refrain from euphoria regarding the effectiveness of this drug.
Gilead is opening up with a large bullish gap. Source: xStation5
3 markets to watch next week - (17.10.2025)
US100 tries to recover🗽Sell-off hits uranium stocks
DE40: European markets decline due to concerns about the U.S. banking sector
Cockroach fears cause stock market sell off, as we wait for clearer details
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
